Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 13/20 | 0.45 |
| ▸ | DRD3 | P35462 | 13/20 | 0.45 |
| ▸ | HTR1D | P28221 | 1/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.43 |
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | DRD5 | P21918 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13144731 | 0.81 | DRD2 (0.51) | DRD2DRD3HTR1DCHRM1DRD4 | |
| SCHEMBL13580305 | 0.79 | DRD2 (0.50) | DRD2DRD3HTR1DCHRM1DRD4 | |
| SCHEMBL1588983 | 0.78 | SIGMAR1 (0.46) | DRD2DRD3CHRM1DRD4DRD1 | |
| SCHEMBL24039955 | 0.78 | DRD1 (0.58) | DRD2DRD3DRD4DRD1DRD5 | |
| SCHEMBL13094748 | 0.78 | DRD1 (0.56) | DRD2DRD3HTR1DCHRM1DRD4 | |
| SCHEMBL29051780 | 0.76 | ESR2 (0.45) | DRD2DRD3HTR1D | |
| SCHEMBL32677899 | 0.76 | DRD2 (0.42) | DRD2DRD3HTR1DCHRM1DRD4 | |
| SCHEMBL32677895 | 0.76 | DRD2 (0.42) | DRD2DRD3HTR1DCHRM1DRD4 | |
| SCHEMBL15775185 | 0.76 | DRD2 (0.42) | DRD2DRD3HTR1DCHRM1DRD4 | |
| SCHEMBL29259622 | 0.75 | DRD2 (0.41) | DRD2DRD3HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4469455-A1 | COMPOUNDS AND METHODS OF USE | Tango Therapeutics, Inc. (US) | 2024-12-04 | — | — | EP | disclosed |
| WO-2023146990-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163048-A1 | COMPOUNDS AND METHODS OF USE | RB1, CYP1B1, REN | DRD2 2290/4885DRD3 2113/4885HTR1D 1462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.